Financing includes $63.5M Series B equity and $20M strategic non-dilutive credit facility Capital supports accelerated scaling amid strong commercial traction with leading biopharmaceutical developers of next-generation precision medicines BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) — Precede Biosciences, a precision diagnostics and data company focused on enabling the next generation of precision medicines, today announced that […]

(NasdaqGM:ORKA), ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in

(NASDAQ:AUTL), Company expects preliminary unaudited AUCATZYL(R) net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025 Autolus anticipates full year 2026 AUCATZYL(R) net product revenue of $120 million to $135 million Independent real-world AUCATZYL(R) data from ROCCA consortium confirm high level of

(NASDAQ:ZUMZ), North America Comparable Sales Increase 6.5%Adjusting Fourth Quarter Outlook Including Raising EPS Guidance LYNNWOOD, Wash., Jan. 12, 2026 (GLOBE NEWSWIRE) — Zumiez Inc. (NASDAQ: ZUMZ) a leading specialty retailer of apparel, footwear, equipment and accessories for young men and women, today announced that the Company's comparable sales for the nine-week period ended January 3,

(NASDAQ:NDLS), BROOMFIELD, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) — Noodles & Company (Nasdaq: NDLS) today released preliminary, unaudited sales results for the fourth fiscal quarter ended December 30, 2025. Preliminary Fourth Quarter of 2025 Sales Results Compared to the Fourth Quarter of 20241: Fourth quarter system-wide comparable sales increased 6.6%, comprised of a 7.3% increase

(NasdaqGM:TARA), On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026 Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support

(NASDAQ:AGIO), AQVESME(TM) (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S. regulatory submission to follow Company progressing early- and mid-stage pipeline in multiple high-value indications Clear path to profitability through the company's existing

(NASDAQ:SNDX), – Approximately $44 million and $125 million in preliminary (unaudited) Revuforj(R) (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increase in Revuforj net revenue in 4Q25 vs. 3Q25 – – $56 million and $152 million in preliminary

(NasdaqGM:MDWD), MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx(R) VALUE Phase III trial in venous leg ulcers (VLUs) expected by year-end 2026; expansion to diabetic foot ulcers (DFUs) and pressure ulcers (PUs) anticipated in 2026 Expanded NexoBrid(R) manufacturing facility fully operational;

(NasdaqGM:NEWT), BOCA RATON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) — NewtekOne, Inc. (“NewtekOne”) today announced that the expiration date with respect to its previously announced offer to exchange (the “Exchange Offer”) its outstanding 5.50% Notes due 2026 (the “Old Notes”) for an equal principal amount of newly issued 8.50% Fixed Rate Senior Notes due 2031